Finance News

BioTime to Present at Oppenheimer 27th Annual Healthcare Conference

1.0 from 2 votes
Monday, March 20, 2017

BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced that Russell Skibsted, Chief Financial Officer, will be presenting at the Oppenheimer 27th Annual Healthcare Conference at the Westin Grand Central in New York City on March 21, at 3:55 p.m. Eastern Time.

A webcast of Mr. Skibsted's presentation at this conference will be available at Replays of the presentation will be available on BioTime's website at

About BioTime

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Our clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of our cell delivery platform is its HyStem® cell and drug delivery matrix technology. The Company's current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. We also have significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. ("Asterias") and OncoCyte Corporation ("OncoCyte"), which we founded and which, until recently, were our majority-owned consolidated subsidiaries.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.

Source: BioTime, Inc.
1.0 from 2 votes
Free Newsletter
Trending News